The Motley Fool

Impedimed Limited share price climbs higher on FDA clearance

The Impedimed Limited (ASX: IPD) share price has had a strong start to the week.

In afternoon trade the medical technology company’s shares are up over 4% to 64.7 cents.

Why have its shares climbed higher?

This morning Impedimed announced that the U.S. Food and Drug Administration has issued a 510(k) clearance to market for its SOZO product designed to aid in the clinical assessment of unilateral lymphoedema in the United States.

This clearance puts the company ahead of schedule for the launch of SOZO in the United States and allows it to expedite its regulatory strategy for additional SOZO indications.

These include fluid status monitoring for patients living with heart failure.

Today’s gain will be a welcome relief to shareholders. The Impedimed share price is down 37% year-to-date.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


Motley Fool contributor Motley Fool Staff has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.